National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury
LEXINGTON, MA – August 3, 2015 Quanterix Corporation, a leader in high definition diagnostics, today announced that JAMA Neurology has published a new study in which its Simoa (single molecule array) technology was used to identify a protein previously linked to acute symptoms following a traumatic…
January 11, 2016
Quanterix announces that it will be presenting at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Frontage Laboratories Announces Partnership with Quanterix and Validation of Simoa HD-1 Analyzer and Software to Support Biomarker Analysis
June 15, 2016
Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, announces that they are the first CRO to complete a GLP validation of the Simoa HD-1 Analyzer and software along with the interface to Watson LIMS.
January 9. 2017
Amended licensing agreement with long-term partner allows Quanterix to continue innovation and commercialization within its expanding fields
Quanterix’ CEO to Host Webinar on the Importance of Biomarkers for the Transformation of Precision Health
June 22, 2017
CEO and Chairman, Kevin Hrusovsky, will be hosting a webinar on the use of ultrasensitive biomarker assays to enable precision health, with a specialty focus on concussion and traumatic brain injury (TBI) detection and diagnostics. Hrusovsky will be joined by Dr. Jessica Gill, Investigator at…
Business Wire| November 27, 2017
Quanterix Corporation today announced the commencement of the initial public offering of shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “Commission”).